When I started MAPS in 1986, the FDA was still blocking all research with psychedelics. MAPS had to try, though we might never succeed, to gather sufficient data about the safety and efficacy of MDMA-assisted …
FOR IMMEDIATE RELEASE: March 07, 2024 [San Jose, California 03/07/24] – MAPS (Multidisciplinary Association for Psychedelic Studies) is excited to announce its collaboration with Texas Eclipse 2024 for …
The stakes were high: This was the final phase — phase 3 — of MAPS’s study aiming to convince the FDA to approve MDMA-assisted therapy for PTSD. Doblin knew that if the participants didn’t see …
It was at an IACP conference in Florida, the largest event for police officers in the world, that Gergerian met Rick Doblin, the former hippie and founder of Maps (an acronym in English for “Multidisciplinary …
Quote Originally appearing here (Archived)
In this conversation, Rick and Isra cover much ground on psychedelics, from set & setting and preparation and integration to Rick’s best practices, personal LSD, MDMA and psilocybin journeys …
You’re having a VR program that’s supposed to somehow remind you of your own inner imagery, so it will be not as precise as your own imagination. -Rick Doblin Originally appearing here (Archived)
“Australia’s policy change is one that every country should consider: suffering people, regardless of nationality, need more opportunities to access novel treatments,” Rick Doblin, executive director …
“Australia’s policy change is one that every country should consider: suffering people, regardless of nationality, need more opportunities to access novel treatments,” MAPS founder and director Dr. …
After decades of criminalization, Australia’s government said Friday that it will legalize the prescription of MDMA and psilocybin for the treatment of two medical conditions, a historic move hailed …
Summary: “At this moment, when two successful Phase 3 studies of MDMA-assisted therapy for PTSD have brought us closer to potential FDA approval than ever before, MAPS and MAPS PBC must faithfully …
In early January, MAPS announced that MAPP2 met pre-specified primary and key secondary endpoints and that it planned to file a new drug application submission in the third quarter of 2023. At the end …